Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

por Anstee, Quentin M., Lucas, Kathryn J., Francque, Sven, Abdelmalek, Manal F., Sanyal, Arun J., Ratziu, Vlad, Gadano, Adrian C., Rinella, Mary, Charlton, Michael, Loomba, Rohit, Mena, Edward, Schattenberg, Jörn M., Noureddin, Mazen, Lazas, Donald, Goh, George B.B., Sarin, Shiv K., Yilmaz, Yusuf, Martic, Miljen, Stringer, Rowan, Kochuparampil, Jossy, Chen, Li, Rodriguez-Araujo, Gerardo, Chng, Elaine, Naoumov, Nikolai V., Brass, Clifford, Pedrosa, Marcos C.
Publicado 2023

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

por Sanyal, Arun J., Lopez, Patricia, Lawitz, Eric J., Lucas, Kathryn J., Loeffler, Juergen, Kim, Won, Goh, George B. B., Huang, Jee-Fu, Serra, Carla, Andreone, Pietro, Chen, Yi-Cheng, Hsia, Stanley H., Ratziu, Vlad, Aizenberg, Diego, Tobita, Hiroshi, Sheikh, Aasim M., Vierling, John M., Kim, Yoon Jun, Hyogo, Hideyuki, Tai, Dean, Goodman, Zachary, Schaefer, Felicity, Carbarns, Ian R. I., Lamle, Sophie, Martic, Miljen, Naoumov, Nikolai V., Brass, Clifford A.
Publicado 2023